Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia
Atemwegsverlauf nach später postnataler Dexamethason-Gabe bei Frühgeborenen mit bronchopulmonaler Dysplasie
Pediatric Pulmonology · 2025-09 · 60 (9)
DOI: 10.1002/ppul.71275 ↗Auf einen Blick
Bei 81 Frühgeborenen mit systemischem Dexamethason endeten 52 % mit Tod oder Tracheostomie. Mehrere klinische Merkmale sagten Tracheostomie oder Tod voraus.
Fragestellung
Ob postnatales Alter und klinische Merkmale bei Frühgeborenen mit bronchopulmonaler Dysplasie Tod oder Tracheostomie nach systemischem Dexamethason vorhersagen.
Methode
Retrospektive Studie bei Frühgeborenen ≤ 30 Schwangerschaftswochen an einem Level-IV-Zentrum von 2009 bis 2019; vollständige Dexamethason-Kur nach 4 Wochen Lebensalter. Analyse per Regression und ROC-Kurven.
Ergebnisse
Von 81 Säuglingen starben 52 % oder benötigten eine Tracheostomie. SGA, spätere postmenstruelle Woche, höherer respiratorischer Support und pulmonale Hypertonie waren mit Tracheostomie assoziiert; AUC 0,87.
Einschränkungen
Retrospektive Studie; weitere Validierung vor klinischer Anwendung erforderlich.
Schlussfolgerung der Autor:innen
Bei Säuglingen mit systemischem Dexamethason wegen schwerer Ateminsuffizienz können klinische Merkmale und das Ausmaß der Atemunterstützung das Ausbleiben des Weanings von positivem Druck vorhersagen.
Kernaussagen
- 81 Frühgeborene erhielten eine vollständige Dexamethason-Kur
- 52 % starben oder benötigten eine Tracheostomie
- Kombination klinischer Merkmale sagte Tracheostomie oder Tod voraus (AUC 0,87)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Journal article in Pediatric Pulmonology, published online on 2025-09-09. Written by Melissa House and 8 co-authors. Institution: Division of Neonatology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Major MEDLINE topics: Dexamethasone, Bronchopulmonary Dysplasia, Glucocorticoids, Respiratory Insufficiency. Cited 1 times so far (Crossref); 33 references. Funded by: The authors received no specific funding for this study..
Topics: Neonatologie
Abstract (original language)
Objective
To wean respiratory support, preterm infants with severe respiratory failure are often administered systemic corticosteroids. We sought to evaluate if postnatal age or clinical characteristics predicted death or tracheostomy following systemic dexamethasone in evolving bronchopulmonary dysplasia. Study Design We performed a retrospective study of infants born at ≤ 30 weeks' gestational age cared for at a Level IV referral center from 2009 to 2019 who received a complete course of systemic dexamethasone beyond 4 weeks of age for the indication of preventing death and/or liberating from positive pressure ventilation. Clinical variables at the initiation of dexamethasone were examined by regression analysis, and receiver operator curves were constructed for their ability to predict death or tracheostomy.
Results
Of the 81 infants that received a complete course of dexamethasone, 52% died or required tracheostomy. At onset of the dexamethasone course, infants ultimately requiring tracheostomy were more likely to be small for gestational age (SGA) ( p = 0.02), receive dexamethasone at a significantly later postmenstrual age ( p < 0.01), require higher respiratory support ( p < 0.01), and have concomitant pulmonary hypertension ( p < 0.01). The combination of SGA, a history of late bacterial sepsis, the need for multiple dexamethasone courses, a diagnosis of pulmonary hypertension, and higher respiratory support at onset of dexamethasone course predicted tracheostomy or death (AUC 0.87).
Conclusion
For infants receiving systemic dexamethasone for severe respiratory failure, a combination of clinical characteristics and magnitude of respiratory support may reliably predict inability to wean from positive pressure ventilation, potentially avoiding ineffective dexamethasone exposure. Further validation is required before clinical use.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Neonatology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Perinatal Institute, Division of Neonatology and Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
ORCID profiles: Thomas Nienaber, Erik B Hysinger, Paul Kingma
Funding
- The authors received no specific funding for this study.
Cite
APA
House, M., Rowe, J., Walters, A., Liu, C., Ehrlich, S. R., Nienaber, T., Hysinger, E. B., Kingma, P., & Ahlfeld, S. K. (2025). Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia. Pediatric Pulmonology, 60(9). https://doi.org/10.1002/ppul.71275
Vancouver
House M, Rowe J, Walters A, Liu C, Ehrlich SR, Nienaber T, et al. Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia. Pediatric Pulmonology. 2025;60(9). doi:10.1002/ppul.71275
BibTeX
@article{House2025,
author = {House, Melissa and Rowe, James and Walters, Audrey and Liu, Chunyan and Ehrlich, Shelley R and Nienaber, Thomas and Hysinger, Erik B and Kingma, Paul and Ahlfeld, Shawn K},
title = {Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia},
journal = {Pediatric Pulmonology},
year = {2025},
volume = {60},
number = {9},
doi = {10.1002/ppul.71275}
}
EUVIMED